FDA’s Social Media Consumer Outreach Up
The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page.
In 2014, The FDA’s Office of External Affairs (OEA) and Center for Drug Evaluation and Research (CDER) began a 90-day pilot program to improve consumer engagement by enhancing its social media responses, specifically to drug related inquiries more quickly and proactively. The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page. The pilot was successful and as a result has become a permanent program.
Other highlights from the social media update are the dashboards offered-OEA Dashboard within the OC Administrative Offices Dashboard. Also noted in the dashboards is the delay of an implementation for an FDA-wide social media policy, targeted now for end of May 2016.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
